Always Remember - Buy The Dip

Sentiment Analysis For CBST

The news is currently generally neutral for CBST.

Based on TextBlob analysis of Yahoo! Finance news summaries for CBST on 2015-03-03.

Yahoo! Finance News for CBST

Merck Closes Tender Offer To Buy Cubist Pharma - Quick Facts
Merck Closes Tender Offer To Buy Cubist Pharma - Quick Facts

Dana Holding To Replace Cubist Pharma In S&P MidCap 400
Dana Holding To Replace Cubist Pharma In S&P MidCap 400

Merck Speeds Up Lung Cancer, HCV Drugs; Filings in 1H15 - Analyst Blog
The race among drug makers in the field of immuno oncology is heating up with Merck & Co. Inc. ( MRK ) disclosing its plans to accelerate the submission of regulatory applications for its key drugs in the oncology

Why Cubist Pharmaceuticals Inc. Stock Skyrocketed 33% in December
What Shares of Cubist Pharmaceuticals , a biopharmaceutical company focused on developing drugs to be used in the acute care environment, skyrocketed 33% in December, based on data from S&P Capital IQ , after

United Therapeutics - DEKA Ink Deal for Remodulin System - Analyst Blog
United Therapeutics Corporation ( UTHR ) entered into a deal with DEKA Research & Development Corp. for the development of a pre filled, semi disposable pump system for the subcutaneous delivery of Remodulin injection to patients suffering from pulmonary

Spectrum/Ligand Pharma Seek FDA Nod for CE-Melphalan - Analyst Blog
Spectrum Pharmaceuticals, Inc. ( SPPI ) announced the submission of a new drug application (NDA) to the FDA for Captisol enabled melphalan (CE melphalan) HCl for injection (propylene glycol free). The company is looking to get CE melphalan approved

Cerus Corporation Reports Phase II Red Blood Cells Data - Analyst Blog
Investors in the pharma biotech sector eagerly wait for pipeline updates as they play an important role in deciding whether or not to invest in a particular company. These updates provide information on experimental drugs and at times give

Tetraphase Hits 52-Week High on Positive Antibiotic Data - Analyst Blog
Shares of Tetraphase Pharmaceuticals, Inc. ( TTPH ) have been riding high after the company announced positive top line data from a phase III study evaluating its experimental antibiotic, eravacycline, for the treatment of complicated intra abdominal infection (cIAI).

Auxilium's Xiapex Gets CHMP Nod for Peyronie's Disease - Analyst Blog
Auxilium Pharmaceuticals Inc. ( AUXL ) and partner Swedish Orphan Biovitrum AB (Sobi) announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has rendered a positive opinion on the approval of Xiapex. The companies

Cubist's Antibiotic Zerbaxa Wins FDA Nod for cUTI and cIAI - Analyst Blog
Great news came in Cubist Pharmaceuticals Inc. 's ( CBST ) way when the FDA approved the company's antibiotic, Zerbaxa (ceftolozane tazobactam). Zerbaxa is approved for the treatment of adults suffering from complicated urinary tract infections (cUTI) and complicated

Merck Up on OncoEthix Acquisition Deal, Oncology in Focus - Analyst Blog
Merck & Co. Inc. ( MRK ) announced that it has acquired through a subsidiary, a privately held Swiss biotech company, OncoEthix, for up to $375 million. Merck's shares were up 2.3% following the announcement. Under the terms of

Tetraphase Spikes on Encouraging Data on Antibiotic - Analyst Blog
Tetraphase Pharmaceuticals, Inc. ( TTPH ) was up 14.5% after the company announced positive top line data from a phase III study evaluating eravacycline for the treatment of complicated intra abdominal infection (cIAI). The randomized, multi center, double blind,

Cubist Gets FDA Approval Of New Antibiotic Zerbaxa
Cubist Gets FDA Approval Of New Antibiotic Zerbaxa

Merck Commences Tender Offer To Acquire Cubist Pharma - Quick Facts
Merck Commences Tender Offer To Acquire Cubist Pharma - Quick Facts

NPS Pharmaceuticals and Shire Up on Takeover Rumors - Analyst Blog
NPS Pharmaceuticals, Inc. ( NPSP ) and Shire ( SHPG ) were up 18.5% and 3.1%, respectively, after a report from Bloomberg indicated that the latter is considering a potential acquisition of the former. As per the Bloomberg report,

Biotech Stock Roundup: Sophiris & Cyclacel Plunge on Data, ChemoCentryx Gains on Positive Results - Analyst Blog
With the holiday season coming up, it's been a relatively quiet week for the biotech sector with very few pipeline and regulatory updates. However, companies like Sophiris ( SPHS ) and Cyclacel ( CYCC ) saw their shares plunging

It's Not the Zombie Apocalypse, but Killer Superbugs Could Be on the Way
Hospital associated MRSA bacteria. Source NIAID via Flickr . Humans are pretty darn lucky. We're surrounded on a daily basis by a number of things that could potentially kill us , including bacteria

Merck-Cubist Deal On Despite Patent Setback, Shares Fall - Analyst Blog
The very day Merck & Co. Inc. ( MRK ) announced its intention to acquire Cubist Pharmaceuticals Inc. ( CBST ) in an all cash transaction valued at about $9.5 billion or $102 per share, the U.S. District Court

Biotech Stock Roundup: Cubist to be Acquired by Merck, Bluebird Shoots Up on ASH Data - Analyst Blog
It was a busy week for the biotech sector with several companies presenting data at the annual meeting of the American Society of Hematology (ASH). Meanwhile, yet another acquisition agreement was announced Cubist Pharmaceuticals ( CBST ) is set

Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling -- Update
Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling -- Update

MARKET SNAPSHOT: The S&P 500 Recorded Its Biggest Drop In Nearly 7 Weeks
MARKET SNAPSHOT: The S&P 500 Recorded Its Biggest Drop In Nearly 7 Weeks

Merck Committed To Cubist Pharma Acquisition Despite Patent Ruling
Merck Committed To Cubist Pharma Acquisition Despite Patent Ruling

Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling
Merck Reaffirms Commitment to Cubist Deal Despite Patent Ruling

Merck Statement On Cubicin Patent Litigation; Cubist Deal To Proceed As Planned
Merck Statement On Cubicin Patent Litigation; Cubist Deal To Proceed As Planned

New Use For AMGN's Old Drug, BLUE In The Pink, Cellceutix Gets A Boost
New Use For AMGN's Old Drug, BLUE In The Pink, Cellceutix Gets A Boost

Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update
Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 6th Update

Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update
Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 5th Update

Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update
Merck to Buy Cubist Pharmaceuticals for $8.4 Billion -- 4th Update

MARKET SNAPSHOT: Energy Companies Drag U.S. Stocks Lower
MARKET SNAPSHOT: Energy Companies Drag U.S. Stocks Lower

Stocks Move Notably Lower Amid Steep Drop By Crude Oil - U.S. Commentary
Stocks Move Notably Lower Amid Steep Drop By Crude Oil - U.S. Commentary